The Italian Society of Drug Addiction Pathologies (SIPaD) has released a comprehensive scientific overview focusing on the evolution of Tobacco Use Disorder (TUD) and the critical role of Harm Reduction in modern clinical practice.
While cigarette smoking remains a leading cause of global mortality—linked to approximately 8 million deaths annually—SIPaD’s multidisciplinary approach aims to offer pragmatic solutions for adult smokers who do not quit.
Key Insights from the Scientific Evidence:
-
The Problem of Combustion: The primary source of harm is tobacco combustion, which generates thousands of toxic and carcinogenic compounds.
-
The Role of Aerosols: Non-combusted alternatives, such as E-cigarettes (E-cigs) and Heated Tobacco Products (HTPs), produce an aerosol rather than smoke.
-
Toxicological Differences: Studies indicate that these products significantly reduce exposure to harmful chemicals—by up to 95-97%—compared to traditional cigarettes.
-
A Structured Medical Framework: For maximum risk reduction, the transition from cigarettes to these devices should occur within a structured healthcare intervention.
A Balanced Clinical Perspective
SIPaD aligns with international health authorities, such as the FDA and the UK Royal College of Physicians, in recognizing that while these products are not risk-free, they present a significantly lower risk than continued smoking.
However, the scientific consensus remains clear: the primary goal must always be the complete cessation of all nicotine and tobacco use. Harm reduction is a vital tool for those who would otherwise continue to smoke, but it must be paired with rigorous prevention to protect non-smokers and youth.
“In the clinical and public health field, the use of E-cigs and HTPs must be considered a risk reduction strategy, not a replacement for the ultimate goal of total cessation.” — SIPaD Position Statement.
